Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients (PLEO-CMT)

Inclusion Criteria: * Male or female, aged from 16 to 65 years; * Patient with a proven genetic diagnosis of CMT1A; * Mild-to-moderate severity assessed by Charcot-Marie-Tooth Neuropathy Score (version 2) with a score \>2 and ≤18; * Muscle weakness in at least foot dorsiflexion; * Motor nerve conduction of the ulnar nerve of at least 15 m/sec; * Providing signed written informed consent to participate in the study and willing and able to comply with all study procedures and scheduled visits. Exclusion Criteria: * Any other associated cause of peripheral neuropathy such as diabetes; * Patient with another significant neurological disease or a concomitant major systemic disease; * Clinically significant history of unstable medical illness since the last 30 days (unstable angina, cancer…) that may jeopardize the participation in the study; * Significant hematologic disease, hepatitis or liver failure, renal failure; * Limb surgery within six months before randomization or planned before trial completion; * Clinically significant abnormalities on the pre-study laboratory evaluation, physical evaluation, electrocardiogram (ECG); * Elevated ASAT/ALAT (\> 3 x ULN) and elevated serum creatinine levels (\> 1.25 x ULN); * History of recent alcohol or drug abuse or non-adherence with treatment or other experimental protocols; * Patient using unauthorized concomitant treatments including but not limited to baclofen, naltrexone, sorbitol (pharmaceutical form), opioids, levothyroxin and…